Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$7.05
+4.0%
$5.62
$3.55
$11.16
$549.91M0.582.93 million shs7.82 million shs
Cyanotech Co. stock logo
CYAN
Cyanotech
$0.36
$3.01
$2.37
$6.29
$2.57M-0.113,483 shs25 shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$3.62
+2.5%
$3.70
$1.92
$11.60
$186.26M2.27349,373 shs244,299 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$79.24
-0.1%
$78.89
$73.31
$134.63
$199.10B0.3813.06 million shs33.83 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%-5.17%+15.90%+17.04%+14.72%
Cyanotech Co. stock logo
CYAN
Cyanotech
0.00%-14.43%+11.96%-14.02%+15.94%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
0.00%-4.08%-13.05%+7.62%+35.25%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-3.03%+1.72%-15.17%-38.07%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
2.2419 of 5 stars
3.52.00.00.01.91.70.6
Cyanotech Co. stock logo
CYAN
Cyanotech
N/AN/AN/AN/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
4.329 of 5 stars
3.04.00.04.63.03.30.0
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9962 of 5 stars
3.25.05.03.93.02.53.8
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
3.00
Buy$20.20186.61% Upside
Cyanotech Co. stock logo
CYAN
Cyanotech
0.00
N/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.00
Hold$9.00148.62% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.43
Hold$109.1937.79% Upside

Current Analyst Ratings Breakdown

Latest ALT, MRK, KOD, and CYAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Cautious
5/14/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$115.00 ➝ $84.00
4/22/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$85.00
4/17/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
4/3/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/31/2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$20K28,583.16N/AN/A$1.74 per share4.05
Cyanotech Co. stock logo
CYAN
Cyanotech
$23.07M0.11N/AN/A$1.33 per share0.27
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.86 per shareN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.10$9.46 per share8.38$18.33 per share4.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)
Cyanotech Co. stock logo
CYAN
Cyanotech
-$5.27M-$0.66N/AN/A-19.50%-44.71%-19.12%N/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.8711.538.000.8227.27%43.23%17.11%7/29/2025 (Estimated)

Latest ALT, MRK, KOD, and CYAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.89-$1.09-$0.20-$1.09N/AN/A
5/13/2025Q1 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million
4/24/2025Q1 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billion
3/27/2025Q4 2024
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.90-$0.84+$0.06-$0.84N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Cyanotech Co. stock logo
CYAN
Cyanotech
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.244.09%N/A47.16%14 Years

Latest ALT, MRK, KOD, and CYAN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/27/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814.18%6/16/20256/16/20257/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
15.85
15.85
Cyanotech Co. stock logo
CYAN
Cyanotech
0.11
1.06
0.28
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
4.62
4.62
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.41
1.16

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Cyanotech Co. stock logo
CYAN
Cyanotech
24.40%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
Cyanotech Co. stock logo
CYAN
Cyanotech
29.10%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
45.90%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5081.11 million77.78 millionOptionable
Cyanotech Co. stock logo
CYAN
Cyanotech
957.16 million5.07 millionNot Optionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9052.76 million28.55 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.51 billion2.51 billionOptionable

Recent News About These Companies

Zacks Research Issues Negative Estimate for MRK Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$7.05 +0.27 (+3.95%)
Closing price 03:59 PM Eastern
Extended Trading
$7.11 +0.06 (+0.88%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Cyanotech stock logo

Cyanotech NASDAQ:CYAN

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$3.62 +0.09 (+2.55%)
Closing price 04:00 PM Eastern
Extended Trading
$3.61 -0.01 (-0.28%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$79.24 -0.05 (-0.06%)
Closing price 03:59 PM Eastern
Extended Trading
$78.72 -0.53 (-0.67%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.